Hebei Changshan Biochemical Pharmaceutical Co Ltd
SZSE:300255
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.68
69.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Hebei Changshan Biochemical Pharmaceutical Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Hebei Changshan Biochemical Pharmaceutical Co Ltd
SZSE:300255
|
56.5B CNY |
-20%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
978.2B USD |
44%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
485.6B USD |
27%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
257.9B CHF |
34%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
206.8B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
265B USD |
38%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
207.5B CHF |
33%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.5T DKK |
42%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
213.9B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
29%
|
Hebei Changshan Biochemical Pharmaceutical Co Ltd
Glance View
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. operates as a key player in the global pharmaceutical industry, with a focused mission of advancing healthcare through innovative biochemical products. Founded in the heartland of China's Hebei province, the company has carved out a niche for itself by specializing in the production of heparin, a critical anticoagulant used in preventing and treating blood clots. Through state-of-the-art biotechnology and substantial R&D investments, Changshan Biochemical has mastered the complex extraction and refining processes that transform raw materials, often sourced from porcine intestinal mucosa, into these essential, life-saving pharmaceuticals. This scientific prowess is not just an end in itself; it represents the backbone of the company's business model, driving both their product portfolio and revenue streams. The company's success is intricately tied to its ability to integrate vertically and scale efficiently, which enhances operational agility and cost management. Such vertical integration involves controlling multiple stages of production—from raw material sourcing and synthesis to finished product distribution—ensuring consistent quality and supply. Moreover, Hebei Changshan's strategic emphasis on innovation allows it to develop new formulations and applications for its biochemical products, expanding its market reach both domestically and internationally. Revenue generation is largely derived from hospital sales, direct pharmaceuticals sales, and partnerships with other biotech firms. By leveraging its biochemical expertise and maintaining robust industry relationships, Changshan Biochemical not only secures its financial performance but also positions itself as a dependable partner in the global healthcare supply chain.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Hebei Changshan Biochemical Pharmaceutical Co Ltd's most recent financial statements, the company has Operating Margin of -20.1%.